San Diego-based Viking Therapeutics marked itself as a significant competitor while in the weight loss drug industry in February soon after revealing promising details from a mid-stage demo of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when presented for a weekly injection and in March the company